Glucose and lipopolysaccharide differentially regulate fibroblast growth factor 21 in healthy male human volunteers – A prospective cross‐over trial

• Published in: Journal of cellular and molecular medicine 2022-12, Vol.26 (24), p.5998-6005
• Main Authors: Pohlhammer, Johannes, Heinzl, Matthias Wolfgang, Klammer, Carmen, Feldbauer, Roland, Rosenberger, Klemens, Resl, Michael, Wagner, Thomas, Obendorf, Florian, Egger‐Salmhofer, Margot, Dieplinger, Benjamin, Clodi, Martin
• Format: Article
• Language: English
• Subjects: Adenosine; Apoptosis; Blood pressure; Body fat; Creatinine; Cross-Over Studies; Cytokines; Deoxyribonucleic acid; DNA; Electrocardiography; fibroblast growth factor 21; Fibroblast growth factors; Fibroblast Growth Factors - metabolism; Fibroblasts; Glucose; Growth factors; Healthy Volunteers; human endotoxin model; Humans; Hyperglycemia; Inflammation; lipopolysaccharide; Lipopolysaccharides; Lipopolysaccharides - pharmacology; Liver; Male; Metabolism; Original; Oxidative stress; Peptides; Prospective Studies; Protein expression; Proteins; Statistical analysis; Variance analysis
• ISSN: 1582-1838; 1582-4934
• DOI: 10.1111/jcmm.17614

Fibroblast growth factor 21 (FGF21) affects the regulation of metabolism. Additionally, anti‐inflammatory properties are attributed to FGF21, and studies in animals and humans show conflicting results. This study aimed to investigate how FGF21 is affected by glucose and lipopolysaccharide (LPS) in humans. Therefore, FGF21 was measured eight times at different time points within 48 h in this prospective cross‐over trial after glucose and LPS on two different study days. The study included ten healthy, non‐smoking male subjects aged 18–40. Repeated measures analysis of variance and paired t‐test as post hoc analysis were applied. The administration of glucose and LPS resulted in a significant difference in regulating FGF21 (p